Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gyawali

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Making adjuvant therapy decisions with uncertain dataB Gyawali, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trialsB Gyawali, Y Ando
Public Health|September 1, 1993
Medical audit of community screening for undescended testes in Halton DistrictB Gyawali, S Bhattacharyya, J A Reid
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2015
Flaws in the trial design of IFCT-0802B Gyawali, T Shimokata, K Honda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2016
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†B Gyawali, T Shimokata, M Ando, et al.
ESMO Open|November 7, 2024
What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists' perceptions on endpoints, benefit, price, and value of cancer drugsS S Datta, V Sharma, A Mukherjee, et al.
JNMA; Journal of the Nepal Medical Association|December 10, 2016
Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic PurpuraB S Poudyal, B Sapkota, G S Shrestha, et al.
ESMO Open|March 13, 2022
"The first ones now, will later be last": understanding the importance of historical context when reading ESMO-MCBS scoresN I Cherny, U Dafni, G Pentheroudakis, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 5, 2020
Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric CancerS J Merchant, W Kong, B Gyawali, et al.
Public Health|July 21, 2022
Cervical cancer screening utilization, and associated factors, in Nepal: a systematic review and meta-analysisA D Shrestha, J G Andersen, B Gyawali, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Making adjuvant therapy decisions with uncertain dataB Gyawali, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trialsB Gyawali, Y Ando
Public Health|September 1, 1993
Medical audit of community screening for undescended testes in Halton DistrictB Gyawali, S Bhattacharyya, J A Reid
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2015
Flaws in the trial design of IFCT-0802B Gyawali, T Shimokata, K Honda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2016
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†B Gyawali, T Shimokata, M Ando, et al.
ESMO Open|November 7, 2024
What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists' perceptions on endpoints, benefit, price, and value of cancer drugsS S Datta, V Sharma, A Mukherjee, et al.
JNMA; Journal of the Nepal Medical Association|December 10, 2016
Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic PurpuraB S Poudyal, B Sapkota, G S Shrestha, et al.
ESMO Open|March 13, 2022
"The first ones now, will later be last": understanding the importance of historical context when reading ESMO-MCBS scoresN I Cherny, U Dafni, G Pentheroudakis, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 5, 2020
Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric CancerS J Merchant, W Kong, B Gyawali, et al.
Public Health|July 21, 2022
Cervical cancer screening utilization, and associated factors, in Nepal: a systematic review and meta-analysisA D Shrestha, J G Andersen, B Gyawali, et al.
Pageof 3